直接口服抗凝药剂量不当的决定因素及医师对临床药师建议的执行情况
该横断面研究纳入2019年某三级医院住院的房颤患者1688例,分析DOAC剂量不适宜(不足或过量)的决定因素及药师建议的接受与执行率。结果显示16.9%的患者存在不适宜处方,剂量不足(9.7%)比过量(6.9%)更常见。体重<60kg、使用艾多沙班、手术史和DOAC初治与剂量不足风险降低相关,而出血史和麻醉药品使用与剂量不足风险升高相关;肾功能不全和体重<60kg与过量风险升高相关,达比加群和艾吡沙班相比利伐沙班与过量风险降低相关。医师接受了79.2%的药师建议。
要点
- 住院房颤患者中DOAC不适宜处方率为16.9%,以剂量不足为主。
- 肾功能不全是DOAC过量的最强相关因素(OR 11.29)。
- 药师建议的医师接受率为79.2%,临床药师服务有助于减少不适宜处方。
核心结论
- DOAC不适宜处方仍常见,但较2016年研究略有改善。
- 药师主导的临床服务可帮助医师减少高危药物(如DOAC)的不适宜处方。
研究设计与样本
- 横断面研究,纳入2019年某三级医院住院的房颤患者1688例。
- 主要结局为DOAC不适宜处方的比例及剂量不足和过量的决定因素。
- 次要结局包括药师建议的接受率和执行率及未接受/未执行的原因。
主要发现
- 16.9%(n=286)的患者存在不适宜处方,剂量不足占9.7%,过量占6.9%。
- 体重<60kg(OR 0.46 [0.27-0.77])、使用艾多沙班(OR 0.42 [0.24-0.74])、手术(OR 0.57 [0.37-0.87])和DOAC初治(OR 0.45 [0.29-0.71])与剂量不足风险降低显著相关。
- 出血史(OR 1.86 [1.24-2.80])和麻醉药品使用(OR 1.67 [1.13-2.46])与剂量不足风险升高显著相关。
- 肾功能不全(OR 11.29 [6.23-20.45])和体重<60kg(OR 2.34 [1.42-3.85])与过量风险升高显著相关。
- 达比加群(OR 0.24 [0.08-0.71])和艾吡沙班(OR 0.18 [0.10-0.32])相比利伐沙班与过量风险降低显著相关。
关键数值与推荐
- 医师接受了179例(79.2%)药师建议,其中剂量不足建议92例(51.4%)、过量建议82例(45.8%)、禁忌症建议5例(2.8%)。
临床怎么用
- 临床药师应重点关注肾功能不全和体重<60kg的房颤患者以预防DOAC过量。
- 对有出血史或使用麻醉药品的患者应警惕DOAC剂量不足。
- 药师应积极参与DOAC处方审核以提高用药合理性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To analyse the appropriateness of direct oral anticoagulant (DOAC) dosing and determinants for under-and overdosing as well as acceptance and implementation rates of pharmacists' interventions. METHODS: Cross-sectional study in a tertiary hospital in hospitalized patients with atrial fibrillation on DOACs in 2019 (n = 1688). Primary outcome was the proportion of patients with inappropriate DOAC prescribing with identification of determinants for under-and overdosing. Secondary outcomes included acceptance and implementation rates of pharmacists' recommendations and determination of reasons for nonacceptance/nonimplementation. RESULTS: Inappropriate prescribing was observed in 16.9% of patients (n = 286) with underdosing (9.7%) being more prevalent than overdosing (6.9%). For all DOACs considered together, body weight<60 kg (odds ratio [OR] 0.46 [0.27-0.77]), edoxaban use (OR 0.42 [0.24-0.74]), undergoing surgery (OR 0.57 [0.37-0.87]) and being DOAC naïve (OR 0.45 [0.29-0.71]) were associated with significantly lower odds of underdosing. Bleeding history (OR 1.86 [1.24-2.80]) and narcotic use (OR 1.67 [1.13-2.46]) were associated with significantly higher odds for underdosing. Determinants with a significantly higher odds of overdosing were renal impairment (OR 11.29 [6.23-20.45]) and body weight<60 kg (OR 2.34 [1.42-3.85]), whereas dabigatran use (OR 0.24 [0.08-0.71]) and apixaban (OR 0.18 [0.10-0.32]) were associated with a significantly lower odds of overdosing compared to rivaroxaban. Physicians accepted the pharmacists' advice in 179 cases (79.2%) consisting of 92 (51.4%) recommendations for underdosing, 82 (45.8%) for overdosing and 5 (2.8%) for contraindications. CONCLUSION: Inappropriate DOAC prescribing remains common, although there is a slight improvement compared to our study of 2016. Clinical services led by pharmacists help physicians to reduce the number of inadequate prescriptions for high-risk medications such as DOACs.
引用
- Moudallel S, Cornu P, Dupont A, et al. Determinants for under- and overdosing of direct oral anticoagulants and physicians' implementation of clinical pharmacists' recommendations. Br J Clin Pharmacol. 2021. PMID: 34331720. doi:10.1111/bcp.15017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。